CN109790155A - 噻吩化合物及其合成方法和其在医药上的应用 - Google Patents

噻吩化合物及其合成方法和其在医药上的应用 Download PDF

Info

Publication number
CN109790155A
CN109790155A CN201780031676.9A CN201780031676A CN109790155A CN 109790155 A CN109790155 A CN 109790155A CN 201780031676 A CN201780031676 A CN 201780031676A CN 109790155 A CN109790155 A CN 109790155A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780031676.9A
Other languages
English (en)
Other versions
CN109790155B (zh
Inventor
王建非
张杨
朱文元
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dongbao Zixing Hangzhou Biomedical Co ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109790155A publication Critical patent/CN109790155A/zh
Application granted granted Critical
Publication of CN109790155B publication Critical patent/CN109790155B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

本发明公开了一类作为尿酸盐转运体(URAT1)抑制剂的噻吩化合物及其在制备治疗尿酸水平异常病症药物中的应用，特别是在制备治疗高尿酸血症和痛风性关节炎药物上的应用。具体涉及式(Ⅰ)所示化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201780031676.9A 2016-05-23 2017-05-23 噻吩化合物及其合成方法和其在医药上的应用 Active CN109790155B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016103433210 2016-05-23
CN201610343321 2016-05-23
PCT/CN2017/085458 WO2017202291A1 (zh) 2016-05-23 2017-05-23 噻吩化合物及其合成方法和其在医药上的应用

Publications (2)

Publication Number Publication Date
CN109790155A true CN109790155A (zh) 2019-05-21
CN109790155B CN109790155B (zh) 2022-02-18

Family

ID=60411095

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780031676.9A Active CN109790155B (zh) 2016-05-23 2017-05-23 噻吩化合物及其合成方法和其在医药上的应用

Country Status (13)

Country Link
US (1) US10829483B2 (zh)
EP (1) EP3466946B1 (zh)
JP (1) JP6724246B2 (zh)
KR (1) KR102244216B1 (zh)
CN (1) CN109790155B (zh)
AU (1) AU2017270858B2 (zh)
BR (1) BR112018074027A2 (zh)
CA (1) CA3025078C (zh)
ES (1) ES2961901T3 (zh)
MX (1) MX2018014374A (zh)
NZ (1) NZ749427A (zh)
RU (1) RU2709473C9 (zh)
WO (1) WO2017202291A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4349414A2 (en) 2014-12-23 2024-04-10 Dyve Biosciences, Inc. Methods and formulations for transdermal administration
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
CN111386268B (zh) * 2017-11-23 2022-04-19 东宝紫星(杭州)生物医药有限公司 一种urat1抑制剂的晶型及其制备方法
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
MX2022004713A (es) * 2019-10-30 2022-05-11 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos.
JP2023506917A (ja) 2019-12-20 2023-02-20 バイエル・アクチエンゲゼルシヤフト 置換チオフェンカルボキサミド、チオフェンカルボン酸およびその誘導体
CN113368073A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的药物制剂的方法
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
CN113368067A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的口服药物片剂的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012050589A1 (en) * 2010-10-15 2012-04-19 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0810524B8 (pt) * 2007-04-11 2021-05-25 Kissei Pharmaceutical derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado
EA018193B3 (ru) 2007-11-27 2014-07-30 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
CN103819419B (zh) * 2008-09-04 2016-12-07 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
ES2662444T3 (es) 2012-11-14 2018-04-06 Teijin Pharma Limited Derivado de piridina
JP6449482B2 (ja) * 2015-03-24 2019-01-09 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合環誘導体、その製造方法、中間体、薬学的組成物及び応用
CN105399694B (zh) * 2015-12-11 2017-09-15 浙江京新药业股份有限公司 药物Lesinurad轴手性对映体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012050589A1 (en) * 2010-10-15 2012-04-19 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AURORA FINE CHEMICALS: "RN 1500276-99-2", 《STN REGISTRY》 *
AURORA FINE CHEMICALS: "RN 1506308-08-2", 《STN REGISTRY》 *
AURORA FINE CHEMICALS: "RN 1506948-73-7", 《STN REGISTRY》 *
AURORA FINE CHEMICALS: "RN 1511846-55-1", 《STN REGISTRY》 *
AURORA FINE CHEMICALS: "RN 1511997-55-9", 《STN REGISTRY》 *
AURORA FINE CHEMICALS: "RN 1516744-39-0", 《STN REGISTRY》 *
AURORA FINE CHEMICALS: "RN 1517276-53-7", 《STN REGISTRY》 *
AURORA FINE CHEMICALS: "RN 1521435-55-1", 《STN REGISTRY》 *
UKRORGSYNTEZ LTD.: "RN 1855720-06-7", 《STN REGISTRY》 *
UKRORGSYNTEZ LTD.: "RN 1866384-17-9", 《STN REGISTRY》 *

Also Published As

Publication number Publication date
AU2017270858A1 (en) 2019-01-17
RU2709473C1 (ru) 2019-12-18
WO2017202291A1 (zh) 2017-11-30
CA3025078C (en) 2021-04-13
RU2709473C9 (ru) 2020-06-16
NZ749427A (en) 2019-11-29
JP2019519606A (ja) 2019-07-11
US10829483B2 (en) 2020-11-10
CN109790155B (zh) 2022-02-18
JP6724246B2 (ja) 2020-07-15
KR20190009377A (ko) 2019-01-28
MX2018014374A (es) 2019-05-20
EP3466946A1 (en) 2019-04-10
ES2961901T3 (es) 2024-03-14
EP3466946A4 (en) 2019-11-06
BR112018074027A2 (pt) 2019-02-26
US20200140423A1 (en) 2020-05-07
KR102244216B1 (ko) 2021-04-26
EP3466946B1 (en) 2023-08-30
AU2017270858B2 (en) 2019-09-19
CA3025078A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
CN109790155A (zh) 噻吩化合物及其合成方法和其在医药上的应用
JP4532274B2 (ja) 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬
US8536221B2 (en) Amide derivatives as positive allosteric modulators and methods of use thereof
US10604513B2 (en) Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases
CN109071538A (zh) 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
TWI714566B (zh) 軸手性異構體及其製備方法和製藥用途
CN107531711A (zh) Janus激酶抑制剂
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
CN108884107B (zh) 乙型肝炎病毒表面抗原抑制剂
AU2007282465A1 (en) Sulfonamide compound or salt thereof
CN109311881A (zh) 新型β-内酰胺酶抑制剂
CN109563051A (zh) 作为pde4抑制剂的并环类化合物
CN116438162A (zh) Mas相关g蛋白受体x4的调节剂及相关产物和方法
CN110418790A (zh) 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物
CN110177774A (zh) 作为Caspase抑制剂的联环化合物
US10017521B2 (en) Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
US20230045031A1 (en) Diarylamide Compound and Application Thereof
KR102660247B1 (ko) 4-(나프탈렌-1-일)-4h-1, 2, 4-트리아졸계 화합물의 결정 형태, 염 형태 및 이의 제조방법
CN114222732B (zh) 一种尿酸促排剂及其合成方法和其在医药上的应用
CN109476677A (zh) 抗hcmv病毒化合物
CN105985334A (zh) 二氮杂-苯并荧蒽并烯类化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Applicant before: MEDSHINE DISCOVERY Inc.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20211201

Address after: 310018 room 1-1008, Heda Medicine Valley Center, 291 Fucheng Road, Xiasha street, Qiantang new area, Hangzhou, Zhejiang

Applicant after: Dongbao Zixing (Hangzhou) biomedical Co.,Ltd.

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230412

Address after: 310018 room 1-1008, Heda Medicine Valley Center, 291 Fucheng Road, Xiasha street, Qiantang new area, Hangzhou, Zhejiang

Patentee after: Dongbao Zixing (Hangzhou) biomedical Co.,Ltd.

Address before: 310018 room 1-1008, Heda Medicine Valley Center, 291 Fucheng Road, Xiasha street, Qiantang new area, Hangzhou, Zhejiang

Patentee before: Dongbao Zixing (Hangzhou) biomedical Co.,Ltd.

Patentee before: Nanjing Mingde New Drug Development Co.,Ltd.